Hytrin: Effective Blood Pressure and BPH Symptom Management
Hytrin
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.95 | $57.00 (0%) | 🛒 Add to cart |
| 90 | $0.86 | $85.50 $77.00 (10%) | 🛒 Add to cart |
| 120 | $0.82 | $114.00 $98.00 (14%) | 🛒 Add to cart |
| 180 | $0.76 | $171.00 $137.00 (20%) | 🛒 Add to cart |
| 270 | $0.73 | $256.50 $198.00 (23%) | 🛒 Add to cart |
| 360 |
$0.72
Best per pill
|
$342.00 $260.00 (24%) | 🛒 Add to cart |
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.43 | $73.00 (0%) | 🛒 Add to cart |
| 60 | $1.90 | $146.00 $114.00 (22%) | 🛒 Add to cart |
| 90 | $1.72 | $219.00 $155.00 (29%) | 🛒 Add to cart |
| 120 | $1.63 | $292.00 $196.00 (33%) | 🛒 Add to cart |
| 180 | $1.54 | $438.00 $278.00 (37%) | 🛒 Add to cart |
| 270 |
$1.49
Best per pill
|
$657.00 $403.00 (39%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.97 | $89.00 (0%) | 🛒 Add to cart |
| 60 | $2.23 | $178.00 $134.00 (25%) | 🛒 Add to cart |
| 90 | $1.99 | $267.00 $179.00 (33%) | 🛒 Add to cart |
| 120 | $1.88 | $356.00 $225.00 (37%) | 🛒 Add to cart |
| 180 | $1.75 | $534.00 $315.00 (41%) | 🛒 Add to cart |
| 270 |
$1.67
Best per pill
|
$801.00 $451.00 (44%) | 🛒 Add to cart |
|
Synonyms
|
|||
Hytrin (terazosin hydrochloride) is a selective alpha-1 adrenergic blocking agent prescribed for the management of hypertension (high blood pressure) and the treatment of symptomatic benign prostatic hyperplasia (BPH). As a first-line therapeutic option, it works by relaxing blood vessels and prostate/bladder neck smooth muscle, facilitating improved blood flow and urinary symptoms. Its dual-action mechanism makes it a valuable tool in cardiovascular and urological practice, offering predictable pharmacokinetics and a well-established safety profile developed through decades of clinical use.
Features
- Active ingredient: Terazosin hydrochloride
- Available in tablet formulations: 1 mg, 2 mg, 5 mg, and 10 mg strengths
- Selective antagonist of postsynaptic alpha-1 adrenergic receptors
- Once-daily dosing regimen for maintenance therapy
- Linear pharmacokinetics with consistent absorption
- Extensive hepatic metabolism with biliary and renal excretion
Benefits
- Effectively lowers both systolic and diastolic blood pressure, reducing cardiovascular risk
- Significantly improves urinary flow rates and reduces BPH symptoms like hesitancy and nocturia
- Demonstrates a rapid onset of action for symptomatic relief in appropriate patients
- Features a long half-life allowing for stable 24-hour therapeutic coverage
- May improve lipid profiles with modest reductions in LDL cholesterol and triglycerides
- Well-tolerated in most patients with side effects typically diminishing over time
Common use
Hytrin is primarily indicated for the management of mild to moderate hypertension, either as monotherapy or in combination with other antihypertensive agents such as diuretics or beta-blockers. In urological practice, it is prescribed for the treatment of symptomatic benign prostatic hyperplasia to relieve symptoms of urinary obstruction, including poor stream, hesitancy, dribbling, and nocturia. Off-label uses may include the management of certain forms of erectile dysfunction and treatment of Raynaud’s phenomenon, though these applications require specialist supervision.
Dosage and direction
For hypertension: Initial dose is 1 mg at bedtime. Dose may be gradually increased to achieve desired blood pressure response. Maintenance dose is typically 2-10 mg administered once daily, with maximum recommended dose of 20 mg/day. For BPH: Initial dose is 1 mg at bedtime, gradually titrated upward to 2 mg, 5 mg, or 10 mg once daily based on symptom response and tolerability. Dose titration should occur at intervals of 2-4 weeks. Tablets should be swallowed whole with water, with or without food, though consistent administration relative to meals is recommended.
Precautions
First-dose hypotension may occur, particularly with initial dosing or dosage increases; administer initial dose at bedtime. Orthostatic hypotension may occur, especially during initial titration. Patients should be cautioned about driving, operating machinery, or performing hazardous tasks during initiation. Use with caution in patients with renal impairment, hepatic impairment, or history of gastrointestinal narrowing. Regular monitoring of blood pressure, prostate-specific antigen (PSA), and urinary symptoms is recommended. Not recommended for use in children.
Contraindications
Hypersensitivity to terazosin, other quinazolines, or any component of the formulation. Concurrent use with other alpha-adrenergic blocking agents. Severe hepatic impairment. History of orthostatic hypotension. Not indicated for use in pediatric patients or women. Contraindicated in patients with a history of micturition syncope.
Possible side effect
Common: Dizziness (19%), asthenia (11%), nasal congestion (6%), peripheral edema (5%), somnolence (5%), nausea (4%), blurred vision (2%). Less common: Palpitations, tachycardia, syncope, dyspnea, weight gain, impotence, priapism. Rare: Urinary incontinence, hematuria, thrombocytopenia. Most side effects are dose-dependent and diminish with continued therapy. Syncope occurs in approximately 1% of patients, typically within 30-90 minutes of initial dose.
Drug interaction
Potentiated hypotensive effects with other antihypertensives, nitrates, phosphodiesterase-5 inhibitors, and alcohol. NSAIDs may diminish antihypertensive effect. Increased risk of hypotension with beta-blockers and calcium channel blockers. Potential interaction with CYP3A4 inhibitors (ketoconazole, ritonavir) may increase terazosin concentrations. Additive effects with other alpha-blockers. Use caution with diuretics and other medications affecting blood pressure.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed dose. If multiple doses are missed, consult healthcare provider before resuming therapy as dose retitration may be necessary. Maintain regular dosing schedule to ensure consistent therapeutic effect.
Overdose
Symptoms may include severe hypotension, dizziness, lightheadedness, syncope, and shock. Management includes immediate cardiovascular support, placing patient in supine position, and administering intravenous fluids. Vasopressors may be required for severe hypotension. Gastric lavage may be considered if ingestion was recent. Dialysis is not effective due to high protein binding. Symptomatic and supportive care is mainstay of treatment.
Storage
Store at controlled room temperature (20-25°C or 68-77°F). Protect from light and moisture. Keep container tightly closed. Do not store in bathroom or near sink. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Properly discard any unused medication after treatment completion.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Hytrin is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to therapy may vary. Patients should consult their healthcare provider for personalized medical advice, including potential risks and benefits specific to their medical condition. Never adjust dosage or discontinue medication without medical supervision.
Reviews
Clinical studies demonstrate Hytrin’s efficacy in reducing blood pressure by 10-15 mmHg systolic and 5-10 mmHg diastolic in hypertensive patients. In BPH trials, peak urinary flow rates improved by 30-40% with significant symptom score reduction. Long-term studies show maintained efficacy over 24+ months of treatment. Patient satisfaction surveys indicate improved quality of life measures related to both cardiovascular and urinary symptoms. Most adverse effects are reported as mild to moderate and transient in nature.